Abbott and J&J start the year from different places
Abbott is cueing up launch after launch for 2020, while J&J is pinning its device hopes to robotic surgery.
Sanofi's geriatric pipeline fails to freshen up
A look at the freshness of pharma's pipelines shows that Sanofi's new chief executive has his work cut out, while Lilly and Astrazeneca come up smelling of…
The sellside falls out of love with Opdivo
An analysis of the sellside’s consensus forecast changes reveals the winners and losers of 2019.
Bioresorbable scaffolds flounder as Reva heads to bankruptcy
With Reva, Amaranth and Abbott out of the game, the pool of dissolving scaffold makers is shrinking.
Biopharma venture financing retreats, but not by much
Private drug developers raised less last year than in 2018, but cash remains plentiful and mega rounds abound.
A thoroughly average year for medtech mergers
Robotic surgery is one of the bright spots in an otherwise tricky year for medtechs seeking a buyer.
Astra and Acasti throw the Amarin bulls more fodder
Amarin must hope that setbacks for Astrazeneca and Acasti show that in Vascepa it has the secret sauce.
What makes a great year for takeovers?
The number of biopharma buyouts overall last year did not rise, though more deals were struck in the “sweet spot”, and premiums saw a healthy rise.
A big finish confirms 2019 as a takeover year to remember
Two megamergers meant that 2019 was always going to be a big year for biopharma M&A in dollar terms – and then came a late flurry of deals.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.